These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 9463793)

  • 1. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.
    Adkins JC; Brogden RN
    Drugs; 1998 Jan; 55(1):121-44. PubMed ID: 9463793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma.
    Dunn CJ; Goa KL
    Drugs; 2001; 61(2):285-315. PubMed ID: 11270943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zafirlukast (Accolate).
    Chung KF; Barnes PJ
    Drugs Today (Barc); 1998 Apr; 34(4):375-88. PubMed ID: 15010725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma.
    Kelloway JS
    Ann Pharmacother; 1997 Sep; 31(9):1012-21. PubMed ID: 9296243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pranlukast: a review of its use in the management of asthma.
    Keam SJ; Lyseng-Williamson KA; Goa KL
    Drugs; 2003; 63(10):991-1019. PubMed ID: 12699401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.
    Menendez R; Stanford RH; Edwards L; Kalberg C; Rickard K
    Pharmacoeconomics; 2001; 19(8):865-74. PubMed ID: 11596838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.
    Virchow JC; Prasse A; Naya I; Summerton L; Harris A
    Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):578-85. PubMed ID: 10934090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials.
    Barnes NC; Miller CJ
    Thorax; 2000 Jun; 55(6):478-83. PubMed ID: 10817796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.
    Lipworth BJ; Dempsey OJ; Aziz I; Wilson AM
    Am J Med; 2000 Aug; 109(2):114-21. PubMed ID: 10967152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
    Nelson HS; Nathan RA; Kalberg C; Yancey SW; Rickard KA
    MedGenMed; 2001 Jul; 3(4):3. PubMed ID: 11549982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.
    Suissa S; Dennis R; Ernst P; Sheehy O; Wood-Dauphinee S
    Ann Intern Med; 1997 Feb; 126(3):177-83. PubMed ID: 9027267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma.
    Jarvis B; Faulds D
    Drugs; 1999 May; 57(5):769-803. PubMed ID: 10353302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of asthma with zafirlukast. Clinical experience and tolerability profile.
    Spector SL
    Drugs; 1996; 52 Suppl 6():36-46. PubMed ID: 8941502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.
    Yurdakul AS; Calişir HC; Tunçtan B; Ogretensoy M
    Respir Med; 2002 May; 96(5):322-9. PubMed ID: 12113382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.
    Busse W; Wolfe J; Storms W; Srebro S; Edwards L; Johnson M; Bowers BW; Rogenes PR; Rickard K
    J Fam Pract; 2001 Jul; 50(7):595-602. PubMed ID: 11485708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of zafirlukast in the treatment of patients with bronchial asthma.
    Tsai JJ; Chan SC; Ho CK; Su YC; Feng TC
    J Microbiol Immunol Infect; 2001 Mar; 34(1):63-70. PubMed ID: 11321130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic profile of zafirlukast.
    Dekhuijzen PN; Koopmans PP
    Clin Pharmacokinet; 2002; 41(2):105-14. PubMed ID: 11888331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group.
    Fish JE; Kemp JP; Lockey RF; Glass M; Hanby LA; Bonuccelli CM
    Clin Ther; 1997; 19(4):675-90. PubMed ID: 9377612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma.
    Dempsey OJ; Fowler SJ; Wilson A; Kennedy G; Lipworth BJ
    Chest; 2002 Jul; 122(1):151-9. PubMed ID: 12114351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma.
    Kemp JP; Minkwitz MC; Bonuccelli CM; Warren MS
    Chest; 1999 Feb; 115(2):336-42. PubMed ID: 10027429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.